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Evaluation and Implementation of a Molecular-Based Protocol for the Identification 
of Enteroviruses at the Florida Department of Health – Tampa Laboratory 
 
Matthew Adams Smith 
ABSTRACT 
  The Enterovirus genus within the family Picornaviridae contains over 100 
serotypes, of which sixty-four are known to be human pathogens.  Infection with this 
group of RNA viruses produces a myriad of clinical conditions including poliomyelitis, 
meningitis, encephalitis, respiratory illnesses, and hand-foot-and-mouth disease.  
Outbreaks have been documented worldwide; significant morbidity and mortality exist to 
warrant laboratory surveillance. 
  Traditionally, enteroviruses have been identified to the level of serotype by the 
serum neutralization assay.  However, numerous problems are associated with this assay.  
The serum neutralization assay is labor intensive, results are often ambiguous, and 
reagents are becoming difficult to obtain.  Recently, molecular-based typing protocols 
have been described that are cost effective and produce results that are more reliable. 
  The overall objective of this thesis was to implement a molecular-based typing 
protocol to replace the serum neutralization method currently used.  Three specific aims 
were identified to reach this objective.  First, a database cataloging all enteroviruses 
isolated at the Florida Department of Health – Tampa Branch Laboratory from 1981 
through 2002 was created.  Serotype prevalence, specimen submission rates, and 
temporal trends were analyzed to demonstrate the public health importance of enterovirus 
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surveillance.  Next, five oligonucleotide primer sets were compared with respect to 
sensitivity, specificity, and overall utility in molecular typing protocols developed to 
accurately determine enterovirus type.  Finally, the most effective molecular assay was 
used to conduct two basic molecular epidemiological analyses of intratypic variation of 
Coxsackievirus B5 isolates, and of intratypic variation of successive Echovirus 9 
passages.   
  The results from this study show that implementation of a molecular-based typing 
system for enteroviruses would be an improvement over current enterovirus serotyping 
methods.  Results are obtained more rapidly and are more reliable.  The implementation 
of such a system would improve the surveillance capabilities of the State of Florida 
Department of Health.  
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Literature Review 
Introduction 
The group of viruses collectively known as the enteroviruses has historically 
been, and continues to represent, a significant public health threat throughout the world.  
In the United States alone, infections with enteroviruses result in an estimated fifteen 
million symptomatic illnesses each year (98).  Enterovirus infections produce a myriad of 
clinical conditions ranging from minor respiratory infections to myocarditis, to severe 
neurological conditions such as encephalitis, meningitis, and poliomyelitis.  The 
Enterovirus family includes dozens of members, most notably poliovirus, perhaps the 
most studied of all known viruses.  In fact, the field of modern virology literally began 
with the discovery of poliovirus.   It was not only the first virus to be propagated in vitro, 
but poliovirus was also the first to be conclusively linked to the etiology of a human 
disease (80).  Although fiercely debated by some, the development of vaccines against 
poliovirus by Jonas Salk and Albert Sabin is generally viewed as a significant victory 
over infectious disease (50).  In the last fifty years poliovirus transmission has been 
drastically reduced worldwide leaving the non-polio enteroviruses as major contributors 
morbidity and mortality. 
The genus Enterovirus is one of the largest members of the family 
Picornaviridae.  Along with the Rhinoviruses, these positive-sense, single-stranded RNA  
(+ssRNA) viruses are responsible for many human infectious diseases.  Other genera in
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 this family include Apthovirus, Cardiovirus, Hepatovirus, and Parechovirus.  These 
vertebrate pathogens are summarized in Table 1.  The Picornaviruses share many 
physical and biological properties such as virion size/shape, buoyant density, receptor 
usage, and infectious cycle.  The origin of the term “picornavirus” can be interpreted as 
either: a) “pico” (Greek for “small”) RNA virus, or b) the acronym Polio, Insensitive to 
ether, Coxsackie, Orphan, Rhino, RNA genome – viruses (7).  All Picornaviruses share a 
common genomic organization with subtle variations that produce the vast phenotypic 
variation of the family. 
Table 1: Members of the Picornavirus Family 
Genus Serotypes Species  Diseases 
Rhinovirus 103 Human; Bovine Respiratory illnesses 
Enterovirus 89 Human; Bovine; Porcine Poliomyelitis; Meningitis; Febrile illness 
Apthovirus 8 Bovine; Porcine Foot and Mouth Disease 
Cardiovirus 2 Human; Murine Encephalitis, Myocarditis 
Hepatovirus 2 Human; Simian Acute hepatitis 
Parechovirus 2 Human Meningitis 
 Adapted from (80). 
 
 In the following sections enterovirus taxonomy, illness, epidemiology and 
infection cycles will be discussed.  A general overview of the molecular biology and 
structure of the virus capsid will follow, as an understanding of these two areas is 
fundamental to the success of molecular methods.  Finally, current detection and 
identification methods will be reviewed. 
Taxonomy 
The Enterovirus genus “officially” includes eighty-nine serotypes of which sixty-
four are known to be pathogenic in humans (89).  Poliovirus, initially isolated in 1919, 
was the first enterovirus to be characterized.  It was later discovered that three distinct 
variants existed (Polio 1, 2, and 3) and though all produced similar pathology, they could 
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not be neutralized by the same anti-serum.  Laboratory advances in culture techniques 
during the 1940’s and 1950’s enabled virologists to isolate new viruses that appeared 
morphologically similar to the polioviruses but were pathologically and antigenically 
distinct.   
The first of these new ‘serotypes’ was isolated in Coxsackie, New York during 
the summer of 1948 from a child suffering from polio-like symptoms.  The ability of this 
virus to produce acute flaccid paralysis in suckling mice led to the establishment of the 
Coxsackie A grouping (77).  Subsequently, isolates were obtained that shared this 
biological trait, yet exhibited significant antigenic variation.  Thus, the Coxsackie A 
(CAV) group was expanded.  These isolates were numbered sequentially CAV1 through 
CAV24, with the first isolate of each serotype considered to be the prototype strain.  
Currently twenty-three serotypes are recognized after it was discovered that CAV23 had 
previously been described as Echovirus 9 (36).   
The Coxsackie B viruses (CBVs) differ from CAVs in regard to their pathological 
effects.  The CBVs were observed to produce a more generalized infection in mice that 
involves not only the central nervous system, but cardiac and adipose tissues as well (72).  
It was later discovered that CBVs grow readily in primary monkey kidney cells, while 
many CAVs do not (31).  Six CBV serotypes were identified from symptomatic patients.  
As more enteroviruses were isolated, it became obvious that no correlation existed 
between clinical disease states and serotype. 
Echoviruses were routinely isolated from healthy individuals throughout the 
1950’s.  These Enteric, Cytopathogenic, Human Orphan viruses were generally found in 
stool samples (21).  An early suggestion was to re-classify these viruses [presumably to 
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one of the CV groups] once a disease state was discovered (31).  As more and more 
echovirus serotypes were identified, it became apparent that the term “orphan” had been 
applied in error.  These viruses were identified as causative agents of meningitis, 
encephalitis, and numerous other clinical illnesses (72).  By 1969, thirty-four echoviruses 
had been identified and the issue of viral disease etiology remained unresolved.  Since 
1970, new enteroviruses have simply been assigned a number, beginning with enterovirus 
68 (52).   
Several enteroviruses have been re-classified since their initial description.   The 
genus Parechovirus, created in 1998, contains two members, formerly echovirus 22 and 
echovirus 23, that differ markedly from other enteroviruses.  This re-classification was 
based upon both genotypic and phenotypic discrepancies (96).  Echovirus 10 was 
renamed Reovirus in 1959 and enterovirus 72 was changed to Hepatitis A virus in 1991 
based upon similar observations (31).  Other taxonomic rearrangements have occurred 
based on the fact that multiple serotypes have been demonstrated to actually be strains 
within the same serotype.  Table 2 summarizes the currently recognized serotypes, along 
with their prototype strains and geographic locations of initial isolation. 
In recent years, molecular data has contributed substantially to viral taxonomy.  
The availability of cost-effective nucleic acid sequencing techniques has resulted in the 
accumulation of an enormous amount of data that was unobtainable just a decade ago.  
One distinct advantage of the use of sequence-derived data in virus taxonomy is that 
phylogeny can more readily be inferred (48).  By comparing nucleotide sequences it is 
possible to determine the extent to which a given group of viruses are related.  For 
instance, the aforementioned re-classifications within the Enterovirus genus become 
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obvious when sequence data are compared and analyzed (57).  Several new enterovirus 
serotypes (EV73 – EV78) have been identified using molecular methods, but have yet to 
be officially recognized (54,56,65). 
Table 2: Currently Recognized Enterovirus Serotypes 
Virus Prototype Origin Virus Prototype Origin 
CA1 Tompkins New York E7 Wallace Ohio 
CA2 Fleetwood Delaware E8 [=E1’]  Ohio 
CA3 Olson New York E9 Hill Ohio 
CA4 High Point North Carolina E10 [=Reovirus]  
CA5 Swartz New York E11 Gregory Ohio 
CA6 Gdula New York E12 Travis Philippines 
CA7 Parker New York E13 Del Carmen Philippines 
CA8 Donovan New York E14 Tow Rhode Island 
CA9 Bozek New York E15 CH 96-51 West Virginia 
CA10 Kowalik New York E16 Harrington Massachusetts 
CA11 Belgium-1 Belgium E17 CHHE-29 Mexico City 
CA12 Texas-12 Texas E18 Metcalf Ohio 
CA13 Flores Mexico E19 Burke Ohio 
CA14 G-14 South Africa E20 JV-1 Washington, D. C. 
CA15 G-9 South Africa E21 Farina Massachusetts 
CA16 G-10 South Africa E22 [=Parechovirus1]  
CA17 G-12 South Africa E23 [=Parechovirus2]  
CA18 G-13 South Africa E24 DeCamp Ohio 
CA19 NIH-8663 Japan E25 JV-4 Washington, D. C. 
CA20 IH-35 New York E26 Coronel Philippines 
CA21 Kuykendall California E27 Bacon Phillipines 
CA22 Chulman New York E28 [=Rhinovirus1]  
CA23 [=Echo 9]  E29 JV-10 Washington, D. C. 
CA24 Joseph South Africa E30 Bastianni New York 
CB1 Conn-5 Connecticut E31 Caldwell Kansas 
CB2 Ohio-1 Ohio E32 PR-10 Puerto Rico 
CB3 Nancy Connecticut E33 Toluca-3 Mexico 
CB4 JVB New York E34 DN-19 [=CA24'] Texas 
CB5 Faulkner Kentucky EV68 Fermon California 
CB6 Schmidt Philippines EV69 Toluca-1 Mexico 
E1 Farouk Egypt EV70 J670 Japan 
E2 Cornelis Connecticut EV71 BrCr California 
E3 Morrisey Connecticut EV72 [=Hepatitis A]  
E4 Pesascek Connecticut P1 Brunhilde Maryland 
E5 Noyce Maine P2 Lansing Michigan 
E6 D'Amori Rhode Island P3 Leon California 
Grey rows indicate serotypes that have been re-classified. Adapted from (9,72) 
 
Based on molecular phylogeny the sixty-four human enteroviruses segregate into 
five distinct clusters.  Five human pathogen species (corresponding to these clusters) are 
recognized within the genus Enterovirus: HEV-A, HEV-B, HEV-C, HEV-D, and PV.  
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These species are demarcated largely according to molecular data.  The International 
Commission on Taxonomy of Viruses considers seventy percent amino acid homology in 
three proteins (P1, 2C, and 3CD) as a defining characteristic of each species (36).  [Note: 
The structural and functional roles of these proteins will be described in more detail in 
subsequent sections.]  HEV-B is the largest species containing CAV9, all CBVs, all 
echoviruses, and EV69 for a total of thirty-six serotypes.  HEV-D, the smallest species, 
contains only two serotypes, EV68 and EV70.  HEV-C contains ten CAVs and is closely 
related to PV, which contains all three poliovirus serotypes (75).  Phylogenetically, the 
PV species cluster tightly with the HEV-C species, however the species remain distinct 
based upon differences in clinical manifestations of infection (31).  HEV-A includes 
eleven CAVs and EV71 (11).  Current data suggest that CAV4 and CAV6, which are not 
assigned to a species, be included with the HEV-A (61).  Variation within serotypes is 
significant at the molecular level and the term “quasi-species” is often used to describe 
individual strains (23).  Figure 1 depicts a dendrogram of the five human enterovirus 
species.  The use of an un-rooted dendrogram implies that a common ancestor has not 
been identified and, consequently, the direction of evolution cannot be inferred.    
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Figure 1: Dendrogram of Enterovirus P1 Nucleotide Sequence  
 
Genetic relatedness of enteroviruses based on the nucleotide sequence of the entire P1 protein.   Note: PV is 
not shown as a separate species, but its genetic relationship to HEV-C is evident.  The E cluster is included 
as an outgroup to demonstrate the divergence of the bovine species which do not cause illness in humans.  
Used with permission (55).  
 
Illnesses 
Most severe of all enterovirus infections is poliomyelitis.  Evidence suggests that 
poliovirus is truly an ancient human pathogen.  Hieroglyphic drawings have been found 
dating back to approximately 1400 BC that depict a young man suffering the effects of 
poliomyelitis (72).  The disease was first described in 1789 by Michael Underwood as a 
“debility of the lower extremities” that typically affected children under the age of five 
(50).  Outbreaks have been described since the 1800’s and the World Health Organization 
is currently conducting a global eradication program that is approaching its goal (35).  As 
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of 2002, poliomyelitis due to poliovirus was endemic to only seven countries and wild 
transmission of PV2 had been eradicated throughout the world (19). 
Classical poliomyelitis is a neurological condition that leads to “acute flaccid 
paralysis.”  Poliomyelitis is the result of virus-induced disruption of central nervous 
system (CNS) function.  Often recovery is slow and one extremity is rendered “lame,” 
while the corresponding limb is unaffected (50).  Atrophy and developmental delay are 
consequences of CNS impairment.  Numerous neurological complications can also arise, 
such as blood pressure irregularities and abnormalities of secretory and excretory organs.  
Acute illness often precedes CNS involvement with fever, headache, and lethargy 
occurring first followed by more sever the neurological symptoms (72). 
Other enterovirus illnesses are generally less extreme than those caused by the 
polioviruses.  Enteroviruses are the most common etiologic agents of aseptic (non-
bacterial) meningitis worldwide (99).  Viral infections of the CNS are secondary in nature 
and their mechanisms have not been elucidated (85).  Echovirus 30 is frequently 
associated with outbreaks of meningitis (6,58).  Unlike that of bacterial origin, 
enterovirus-derived meningitis is generally self-limiting, with adults often remaining 
symptomatic longer than children (87).  Fever, headache, and malaise are often observed.  
Encephalitis is a more serious condition but its incidence is markedly lower.  Global 
neurological depression (i.e. confusion, weakness, and irritability) can occur suddenly, 
preceding seizure and even coma in extreme cases (86). 
Respiratory illnesses are another characteristic clinical outcome of enterovirus 
infection.  Up to fifteen percent of all upper and lower respiratory infections can be traced 
to an enterovirus origin (20).  Croup, “common cold,” and epiglottis (upper respiratory 
  9 
 
 
 
 
infections) are most often observed (72).  General “flu-like” symptoms are quite common 
manifestations of enterovirus infection.  These illnesses are quite often misdiagnosed or 
undiagnosed due to the vagueness of symptoms (87).  Herpangina and hand-foot-and-
mouth disease affect children and are usually accompanied by characteristic “rashes” 
(72).  Despite their namesake, enteroviruses do not routinely cause enteric illnesses (51).  
One notable exception is Hepatitis A (formerly known as enterovirus 72), which is 
commonly implicated in food-borne outbreaks.   
Disseminated infections can lead to a variety of pathologies including 
myocarditis, pleurodynuria, and conjunctivitis.  All of these conditions are generally self-
limiting, although chronic infections are sometimes observed.   Selenium deficiency has 
been reported to be a risk factor for myocarditis, leading to regions of high endemicity in 
China (73).  Enterovirus etiology of rheumatic heart disease has also been described (40).  
Pleurodynia, or muscle disease, is not commonly encountered, but can be quite a serious 
condition affecting the musculature of the ribcage.  Conjunctivitis is caused primarily by 
EV70 and CA24, and generally is transmitted via inoculation into the eye (51).   There 
are reports of an association of chronic enterovirus infection with diabetes, but the 
epidemiological data is not entirely conclusive (68). 
Newborns suffer the greatest risk of poor clinical outcomes.  Multi-system 
hemorrhagic disease of infants or “sepsis-like” disease is a potentially fatal disorder often 
caused by E11 and E19 (44).  Infants can experience elevated morbidity and mortality 
due to diminished immune system function, especially in the absence of maternally 
acquired anti-bodies (1).  Perinatal infections can be quite serious and have been shown 
to be associated with neurodevelopmental delays (25). 
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Epidemiology 
 Enteroviruses cause numerous disease states and do not follow clearly 
recognizable epidemiological patterns.  Infections are generally self-limiting and often 
asymptomatic, reflecting an evolutionary balance between virus and host.  Over ninety 
percent of poliovirus infections have been shown to lack clinical symptoms (50).  On the 
other hand, virulent strains of other enteroviruses have been documented that produce a 
disproportionate amount of serious illness (58,92). 
 Enterovirus transmission is known to proceed by four mechanisms.  Infections 
have been shown to occur via the following fecal-oral, respiratory, inoculation, and 
blood-borne routes (51).  Fecal contamination of fomites and perinatal transmission to 
newborns are responsible for a large percentage of enterovirus outbreaks (72).  This 
model can also be applied to developing countries where water quality and general 
hygiene are often inadequate to prevent infections (51).  Enteroviruses are shed in stool at 
high concentrations, are capable of persisting in the environment for extended periods, 
and are transmissible via sewage-contaminated water (72).  
These modes of transmission produce some general temporal and demographic 
features of enterovirus infection.  In temperate climates, enterovirus infections are most 
prevalent during the summer months, but can occur year-round in tropical and sub-
tropical climates (51).  Children are often at higher risk of infection due to increased 
contact, poor hygiene, and absence of IgG generated from previous exposure (21).   
It is known that serotype prevalence varies annually.  National trends have been 
documented, but are skewed due to under/over-reporting in various regions (98).  In 
2002, E18 and E13 accounted for over sixty percent of all enteroviruses isolated in the 
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United States as reported by the National Enterovirus Surveillance System (18).  
However, from 1993 to 2001, these two serotypes accounted for less than five percent of 
all isolates (16,17).  Data from this passive surveillance mechanism is several biases. 
Serotypes that grow readily in culture and are easily typed via serum neutralization will 
tend to be isolated and identified more frequently. In addition, specimen submission for 
typing will be skewed in favor of serotypes that cause more severe illness.  Echovirus 30, 
E11, and CB5 are prevalent perennially and have been linked to numerous outbreaks 
worldwide (37,52,63).  Variant strains of E30 have been described which exhibit distinct 
epidemiological patterns (70).  
Several EV71 outbreaks have occurred in the recent years in the South-Pacific.  
Hand-foot-and-mouth disease, the primary clinical syndrome caused by EV71, is 
generally non-life-threatening and occurs mainly in children.  The virus has caused some 
outbreaks of polio-like illness, complicating eradication and surveillance efforts (22).  
Encephalitis and pulmonary edema have been observed in a disproportionate number of 
cases during these outbreaks (92).  These epidemics have been characterized by 
abnormally high infection rates and increased case-fatality rates (49).  Between 1997-
2001, 159 deaths due to EV71 infection have occurred in Malaysia and Taiwan alone 
(42).  Numerous molecular epidemiological studies have been conducted, but neither the 
mechanism nor origin of this increase in virulence is understood (12,30).  It has been 
hypothesized that the differential cell tropism of EV71 relative to other enteroviruses may 
be a key factor in these outbreaks (104). 
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Infection Cycle 
 Despite wide variation in clinical manifestations, the primary route of enterovirus 
infection is through the alimentary tract.  Since fecal-oral transmission is the predominant 
mode of enterovirus transmission, virions must be capable of surviving in the gut at least 
long enough to initiate an infection.  Enteroviruses are resistant to both low pH (<2) and 
enzymatic degradation (74).  Figure 2 depicts the general course of enterovirus infection.   
 Receptor binding is the first of several steps in the course of infection.  Numerous 
receptors, with which enteroviruses interact, have been identified.  Polioviruses recognize 
the molecule CD155, also known as the “poliovirus receptor” (83).  The CAVs and CBVs 
both recognize different receptors: intercellular adhesion molecule (ICAM-1) and 
coxsackie-adenovirus receptor (CAR), respectively.  Echoviruses recognize other 
molecules including delay-accelerating factor (DAF) and CD55 (82).  These molecules 
tend to be membrane-spanning glycoproteins with multiple extra-cellular domains (8).  
Variation in receptor structure is well documented and most certainly plays a role in not 
only tissue tropism, but clinical disease as well (4).  Genes encoding these various 
receptors have been shown to exhibit extreme variation.  It is likely that different allelic 
forms of receptors are correlated with severity of disease (34). 
Upon binding to an appropriate receptor, enteroviruses must insert their nucleic 
acid into the host cell.  Individual enterovirus virions undergo a conformational change 
upon receptor recognition (29).  These particles have altered physical properties that 
allow cellular uptake of the virus (79).  Endosome-mediated transport delivers 
enterovirus particles to the cytoplasm where they are quickly degraded to release the 
infectious RNA (95). 
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Figure 2: Route of Enterovirus Infection 
 
Route of entry and locations of enterovirus infection.  Used with permission (79). 
 
 
    Pocket factors have been identified that appear to be necessary for viral entry.  
These compounds are generally long-chain fatty acids that stabilize the altered 
conformation facilitating efficient delivery of the genome into the cell (94).  Competitive 
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inhibition of these molecules is a promising area of anti-viral research (84).  A series of 
molecules known as the WIN compounds (so named because they were developed by 
Sterling-Winthrop Pharmaceuticals) have been shown to drastically reduce the infectivity 
of enteroviruses in vitro (87).  Synthetic peptides that block the virus-receptor interaction 
(through similar mechanisms) have also been proposed as therapeutic options (26,78).   
 Enterovirus replication proceeds in the cytoplasm of infected cells (27).  Viral 
RNA is first transcribed to a negative strand intermediate, which is then transcribed to the 
positive strand RNA (33).  As viral RNA accumulates in infected cells, pathological 
changes begin to occur, although their biochemical mechanisms are not currently 
understood (2).  Most notable of these alterations are the inhibition of both host cell 
transcription and translation, and the increase in permeability of the cell membrane (100).  
The increased permeability of the host cell membrane leads to lysis and is generally 
considered the underlying cause of cytopathic effect observable in infected, cultured cells 
(90).  Upon lysis, viral progeny are released into the bloodstream and either initiate 
secondary viremias or are excreted.  Thus, it is not surprising that enteroviruses can be 
isolated from a variety of tissues and sample types. 
Molecular Biology 
Genome organization and capsid structure are highly conserved throughout the 
family Picornaviridae, and especially within the genus Enterovirus.  Slight differences 
demarcate species, but generally these are relatively minor variations pertaining to 
receptor recognition, protein processing, or lengths of non-translated regions.  The 
enterovirus genome is approximately 7500 nucleotides and is arranged in a single open 
reading frame (ORF).   This multiple protein coding sequence is flanked on both the 5’ 
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and 3’ ends by non-translated regions (NTRs).  Although these regions do not code for 
proteins, their functions are vital to the infection cycle.  While a 3’-poly-adenine tail is 
present, enteroviruses lack a 5’-methyl-cap. 
The 5’NTR is comprised of approximately 740 nucleotides with a highly 
conserved secondary structure (stem loop) that is often referred to as the “cloverleaf” 
(28).  Downstream of this loop is the internal ribosome entry site (IRES), which is 
involved in the initiation of cap-independent translation (106).    Induction of this 
alternate form of translation is crucial in host cell translation shutoff and allows viral 
progeny to be preferentially propagated (105).  The 3’NTR, approximately seventy to one 
hundred nucleotides in length, forms a pseudoknot-like element (PKLE).  This structure 
is thought to be involved in (-) strand RNA synthesis, the first step in viral replication 
(106).  The 3’-poly-adenine tail is of variable length (thirty to one hundred nucleotides), 
and is required for infectivity (80).  Both non-translated regions are highly conserved due 
to the functional aspects of their secondary structure (76). 
The single ORF codes for all structural and functional proteins.  Proteolytic 
processing produces multiple proteins from the polypeptide.  Virally-encoded proteases 
cleave nascent chains in precise locations which are highly conserved throughout the 
family Picornaviridae (7).  Several processing intermediates play vital functional roles, 
reflecting an evolutionary trend towards efficient utilization of a relatively compact 
genome  (28).  Figure 3 summarizes the genomic organization of the enteroviruses. 
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Figure 3: Enterovirus Genomic Organization 
1A 1B 2B1D1C 2A 2C 3A 3C 3D
VP4 VP2 VP1 VPgVP3
Structural Functional
5’ 3’P1 P3P2
The enterovirus genome, 5’ to 3’, with the relative size of each protein shown to scale.  The 5’- and 3’-
NTRs are not shown to scale. 
  
Three distinct regions comprise the ORF, which is approximately 6700 
nucleotides in length.  The P1 region codes for the viral capsid proteins, which are 
described below.  These proteins are translated first and self-assemble to form capsids 
within the cytosol (29).  The P2 and P3 regions encode proteases and other functional 
proteins crucial to the replication cycle.  The 2A protease initially separates the P1 region 
from the P2-P3 peptide via an autocatalytic mechanism (80).  The 3C and 3CD 
proteinases carry out subsequent cleavages (33).  The 3D RNA-dependent Polymerase is 
the last protein translated and synthesizes (-) strand RNA (28).  This enzyme lacks 
“proofreading” and its high error rate reinforces enterovirus variation (24).  The VPg 
protein (also known as 3B) is crucial in linking replicated RNA to the capsid (33).  Other 
proteins (2B, 2C 3A) play minor, but crucial roles in the replication cycle.  
Capsid Structure 
 The ninety-seven kD P1 region represents roughly forty percent of the ORF and is 
cleaved to form the four capsid proteins VP1-VP4 (29).  These proteins assemble to form 
the 30nm diameter icosahedron capsid.  VP1, VP2, and VP3 are all approximately the 
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same size, while VP4 is much smaller.  Sixty copies of each protein are present in the 
capsid.  This number is absolutely critical to capsid geometry and does not vary (29).   
The protomer is the building block of the capsid.  Each protomer is composed of 
one copy each of the VP1-VP4 proteins.  VP1, VP2, and VP3 form the exterior surface, 
while VP4 lies on the interior.  The external peptides (VP1-VP3) are composed of eight 
anti-parallel β-sheets and two α-helices on each terminus; the internal peptide (VP4) is 
composed of only two β-sheets (7).  Five protomers assemble to form a pentamer; twelve 
pentamers combine to form the capsid.  A diagram of the enterovirus capsid is provided 
in Figure 4.  Two distinct types of symmetry axes are formed: three-fold and five-fold.  
Numerous depressions are formed on the capsid surfaces due to cumulative molecular 
interactions of the peptides.  Near the five-fold symmetry axis a groove is formed which, 
according to the “canyon hypothesis,” facilitates receptor binding (93).   
Capsid structure, although highly ordered, is significantly divergent across the 
genus Enterovirus and throughout the family Picornaviridae.  The P1 region as a whole 
is much more divergent than the P2 and P3 regions (29).  In fact, it is the variation in the 
capsid proteins that define serotypes (80).  The ability to elicit an immune reaction with a 
specific monoclonal antibody is the hallmark trait of a serotype (72).  For instance, the 
same mono-clonal antibody will not recognize both CB1 and CB2.  Antibodies bind to 
specific protein structures based upon the specificity conferred by their long and short 
chains.  The ability of specific antibodies to neutralize enteroviruses has been the primary 
means of determining serotype for decades (described in more detail below). 
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Figure 4: Enterovirus Capsid Structure  
  Three proteins are involved in protomer formation.  These protomers assemble to from the capsid.   
  Adapted from (3). 
 
 
Neutralization sites have been characterized for many enteroviruses.  Techniques 
such as X-ray crystallography and cryo-electron microscopy have elucidated antibody-
virus interaction at extremely high resolutions (97).  The VP1 protein has been shown to 
contain the majority of these neutralization sites (39).  The structures of “loops” 
protruding from the capsid surface confer serotype specificity (47).  These loops link the 
eight β-sheets and are named accordingly with the sheets they connect.  For example, the 
AB loop links the A and B sheets, both of which are embedded in the capsid surface.  
VP1 has three such loops, while VP2 and VP3 have two each (7).  The BC loop in 
particular has been shown to be involved in neutralization (54).    
Detection and Surveillance 
 While some may argue that enterovirus detection alone is sufficient, 
determination of serotype is often advantageous.  It is important to note that clinical and 
public health needs are often not identical.  The ability to differentiate between polio and 
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non-polio enteroviruses is critical in regions where polio is endemic and active 
surveillance is being conducted (52).  Differentiation among PV strains (intratypic 
variation) is also desirable as certain strains may differ in their ability to produce serious 
illness (101).  Identification of epidemics is quite beneficial from a public health 
standpoint.  Some enterovirus serotypes tend to be perennially endemic in certain areas, 
while others are associated with infrequent outbreaks (72).  Finally, the isolation and 
characterization of new serotypes is only possible if identification (subsequent to 
detection) is pursued (52).   
 Traditionally serological assays have been the method of choice in enterovirus 
identification.  Inoculation onto cultured cells subsequent to appropriate specimen 
preparation has been used in clinical virology laboratories to identify virus infection for 
decades.  A large number of different assays can be used to identify the infectious agent.  
Three of the most common include complement fixation, fluorescent antibody, and serum 
neutralization.  Each of these assays exploits a specific antigen-immune response 
relationship and the use of each is indicated indifferent occasions.  Depending on the 
particular assay design, the presence/ absence of an immune reaction is indicative of 
infection with a particular agent.   
Viral isolation from culture is generally used to detect enterovirus infection (103).  
Due to their large range of tissue tropism, enteroviruses can be isolated from a variety of 
different specimens, including: stool, CSF, blood, serum, and nasal/throat swabs (88).  
Enteroviruses produce a distinct and easily recognizable CPE in cultured cells.  Most 
enteroviruses will grow readily in BGM cultures, although some serotypes are difficult to 
culture (5).  Additionally, many of the CAVs propagate only in suckling mice (79).   
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The serum neutralization assay is considered the “gold standard” to identify 
serotype once an enterovirus has been isolated in culture.  This assay, perfected in the 
1950’s, uses eight intersecting pools of antisera to determine serotype (41).  Once CPE is 
observed in the initial culture, the suspected enterovirus is titrated to a concentration of 
100 TCID50.  This concentration of virus is sufficient to demonstrate a neutralization 
reaction, but is not so high as to overcome the antibodies present in the antisera.  
Incubation of virus in the presence of homologous antisera will cause the virus to be 
neutralized (i.e. diminished observable CPE).  The serum-virus mixture is then inoculated 
into multiple cultures of host systems.  Depending on which of the eight anti-sera pools 
produce neutralization reactions, serotype can be inferred by means of a chart.  These 
reactions can be performed in either test tubes or ninety-six well plates. 
Significant drawbacks exist with the serum neutralization assay.  Most significant 
(at least in terms of clinical utility of laboratory diagnosis) is the time required for 
detection and identification.  Some serotypes take weeks to produce observable CPE.  
This coupled with time required to titrate the virus and perform the actual neutralization 
test can lead to diagnostic “lags” of over one month.  Blind passages are often required, 
adding to the time and cost of the assay (13).  Even when performed correctly, the 
neutralization assay may fail due to antigenic drift, virus aggregation, or the presence of 
multiple serotypes (66).  The test is expensive, and the results may be difficult to interpret 
(102).  The handling of live, infectious viruses requires extensive staff training and can be 
dangerous if performed improperly.  The maintenance of continuous cell culture lines is 
prohibitively expensive to many laboratories.  Even reagents are difficult to obtain as 
they are produced by WHO and distributed somewhat sparingly (52).  These WHO pools 
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only include anti-sera to forty serotypes.  Supplemental pools and individual serotype-
specific antisera are required for the identification of all sixty-four serotypes (64).   
In a quality assessment survey of twelve European virology laboratories 
conducted in 1995, the difficulties of enterovirus identification were demonstrated (102).  
Each laboratory was sent a proficiency panel of ten specimens, which contained one, two, 
or no enteroviruses.  The serotypes represented in this panel (P1, P2, P3, CA7, E4, E6, 
E30, EV71, CB3, and E11) were all common serotypes, known to produce strong CPE in 
susceptible cell lines.  Clearly, there is a need to develop more reliable, unambiguous, 
time-efficient methods to identify enteroviruses.     
It is not surprising that a host of new diagnostic tools have been utilized in recent 
years.  Immunoperoxidase tests, hybridization assays, RFLP, and microchip array 
technology have been used for the detection and/or serotyping of enteroviruses from a 
variety of specimens (10,46,91).  Among these, RT-PCR is currently the most widely 
used procedure.  Increased sensitivity and turnaround time are two of the major 
advantages of RT-PCR.  Some virologists advocate that routine diagnostic cell culture 
should be abandoned in favor of nucleic acid amplification methods (13).  This position, 
however, is strongly opposed by others who claim that elimination of cell culture would 
lead to the inability to recognize novel viruses (67).  RT-PCR assays for enterovirus 
detection often utilize oligonucleotide primer sets that anneal to the highly conserved 5’-
NTR region.  These “pan-enterovirus” primers can detect virtually all enterovirus 
serotypes, as well as some rhinoviruses (88).  However, due to the lack of variation in the 
amplicon, these primers are of limited utility for molecular typing.  It has been shown 
that no reliable correlation exists between 5’NTR sequence and serotype (38). 
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Numerous RT-PCR assays have been developed that utilize oligonucleotide 
primers that anneal to sequences encoding the capsid proteins.  Sequence analysis of the 
amplicon can be used to determine serotype.  Primer design, however, is crucial: primers 
must anneal to conserved regions, but produce a relatively divergent amplicon.  The VP2 
region sequence was shown to poorly correlate with serotype since expected branch 
points were not observed when phylogenetic trees were constructed (62).  The VP4 
region has been used with some success in Japan, but likely suffers some limitations 
because VP4 is located on the interior of the enterovirus capsid and is not exposed (32).    
The VP1 region has been used extensively for molecular typing of enteroviruses.  
The sequence of the VP1 region has been documented to highly correlate with serotype 
due to the large number of neutralization sites present on the VP1 surface.  Often these 
assays utilize highly degenerated oligonucleotide primer sets that contain “wobbles” and 
deoxyinosine residues.  These primer modifications allow the primer to tolerate some 
variation in target sequence.  Subsequently, these primers are capable of amplifying many 
different serotypes.  The deoxyinosine residues will bind to any base, but reaction 
kinetics involved lead to decreased sensitivity (60).  Thus, it is often difficult to obtain 
“sequencable” amplicons from clinical specimens.  Most VP1 assays still require that an 
enterovirus be cultured in order to obtain virus concentrations significantly higher than 
those present in clinical specimens (69). 
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Objectives 
 The scope of this study pertains to enteroviruses isolated in the Virology Section 
of the Florida Department of Health – Tampa Branch Laboratory from 1981 to present.  
The primary objective  of this project was to implement a molecular-based protocol for 
the identification of enterovirus serotypes that could replace the serum neutralization 
assay currently in use.  Three specific aims were outlined for the study: 
1) Descriptive Epidemiology – Data on enterovirus isolation since 1981 was 
analyzed for descriptive epidemiological parameters, and compared to 
national trends.  Seasonality, serotype distribution, year-to-year variation, and 
specimen submission trends were evaluated. 
2) RT-PCR Assay Comparison – Five VP1 oligonucleotide primer sets were 
examined for their efficacy in enterovirus detection relative to a 5’NTR assay.  
Assays were compared on the basis of sensitivity, specificity, positive 
predictive value, and negative predictive value. 
3) Sequence Analysis – The best-performing molecular assay was used to 
determine serotype of enteroviruses via nucleotide sequencing of amplicons.  
Various analysis algorithms were compared relative to serum neutralization 
results.  Two additional analyses were performed to exemplify the overall 
utility of the developed protocol; one investigating intra-serotypic divergence, 
and the other examining the effects of sequential in vitro passages.   
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Materials and Methods 
Database Creation 
 Microsoft Access® was used to create a database cataloging all enteroviruses 
isolated at the Florida Department of Health – Tampa Branch Laboratory.  Two thousand 
one hundred fifty specimens from 1981 through 2002 were entered.  The fields included 
were: lab identification number, specimen type, date inoculated, and serotype 
(determined via SN assay).  Where applicable, multiple specimens from the same patient 
were noted as “duplicate” to ensure that double counting did not occur.  Of the 2150 
isolates, 159 such duplicates were removed from analysis, leaving 1991 unique isolates.  
Performance evaluation samples were not entered into the database.  Although only 
viruses isolated from patients were used, not all isolates were from symptomatic cases.  
In accordance with the IRB Category Four exemption status (IRB #100880), only 
laboratory identification numbers were used in this study.  No client information was 
available to the investigator. 
 Microsoft Excel® was used to analyze the above data for general descriptive 
epidemiology.  Serotype frequency was determined for the entire period as well as 
multiple intervals within the twenty-two year window.  Temporal dynamics (i.e. 
seasonality) were explored using various queries to the original database and subsequent 
export to Excel®.  Sample submission was analyzed in a similar manner.  Data obtained 
was compared with nationwide data reported by CDC.
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Virus Panel Preparation 
A panel of fifty-six distinct enterovirus isolates was prepared for use in this study.  
The prepared panel included: twelve CAV serotypes (CAV2-10, CAV13-14, and 
CAV16), six CBV serotypes (CBV1-6), twenty-seven echovirus serotypes (E1-6, E6”, 
E7, E9, E11, E11’, E12-E21, E24-25, E27, E30, E31, and E33), three EV serotypes 
(EV68 and EV70-71), three PV serotypes (P1-3), and five serotypes which have since 
been re-classified (E8 → E1’, E10 → Reovirus, E22-23 → Parechovirus1-2, and EV72 
→ Hepatitis A).   The re-classified serotypes were included for reference because at one 
time they  were all considered to be enteroviruses.  No archived isolates were available 
for fifteen serotypes (CA1, CA11-12, CA15, CA17-22, CA24, E26, E29, E32, and 
EV69).  Financial restrictions and infectious substance shipping regulations made 
obtaining these serotypes impractical.  Table 3 lists all serotypes used in this study. 
Eight serotypes (CA2-6, CA8, CA10, and CA14) were originally propagated in 
suckling mice and therefore not cultured.  Hepatitis A was not cultured due to a lack of a 
cytopathic strain.  Coxsackievirus B6 was not cultured because no archive was available; 
a performance evaluation isolate was used instead.  Although these ten viruses were not 
cultured, they were still included in molecular testing as described below. 
Forty-six serotypes were propagated in buffalo green monkey kidney (BGM), 
rhesus monkey kidney cells (RMK), or normal fetal human lung (MRC-5) cell lines.  
BGM and MRC-5 cells are cultivated in-house by a dedicated cell-culture technologist.  
These are continuous cell lines routinely used for diagnostic isolations at the Tampa 
Branch Laboratory.  RMK cells are received weekly from Viromed® (Minnekota, MN; 
catalog # 14-309). 
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Table 3: Isolates Used in This Study 
Serotype Cultured Serotype Cultured Serotype Cultured Serotype Cultured 
CA2 No CB3 Yes E10 (Reo) Yes E23 (PEV2) Yes 
CA3 No CB4 Yes E11 Yes E24 Yes 
CA4 No CB5 Yes E11' Yes E25 Yes 
CA5 No CB6 No E12 Yes E27 Yes 
CA6 No E1 Yes E13 Yes E30 Yes 
CA7 Yes E2 Yes E14 Yes E31 Yes 
CA8 No E3 Yes E15 Yes E33 Yes 
CA9 Yes E4 Yes E16 Yes EV68 Yes 
CA10 No E5 Yes E17 Yes EV70 Yes 
CA13 Yes E6 Yes E18 Yes EV71 Yes 
CA14 No E6" Yes E19 Yes EV72 (HAV) Yes 
CA16 Yes E7 Yes E20 Yes P1 Yes 
CB1 No E8 (E1’) Yes E21 Yes P2 Yes 
CB2 No E9 Yes E22 (PEV1) Yes P3 Yes 
 
Isolates were removed from the -70°C archive freezer and rapidly thawed in 37°C 
water bath.  Prior to inoculation, cell cultures in 15 x 125cm2 screw cap culture tubes 
were washed with 2ml Eagle’s Balanced Salt Solution (EBSS).  Excess fluid was poured 
off and 100µl of undiluted stock solution virus was inoculated into tube using sterile 1ml 
pipettes.  Tubes incubated in inclined racks for two hours on a rocking platform at 37°C.   
Eagle’s Minimum Essential Media (EMEM), 5% fetal calf serum (2ml) was added to 
each tube.  Tubes were incubated in a rotating rack at 37°C.  Negative controls (non-
inoculated tubes) were always included when performing inoculations. 
Cells were examined with an inverted light microscope seventy-two hours post-
inoculation.  Additional observations were performed daily.  Cytopathic effect was 
scored on a scale of “0” to “4.”  This scale refers to observable changes that occur in 
cultured cells upon virus infection: “0” represents no visible cytopathic effect, “1” 10-
25% of cells appear lysed and shriveled, “2” 25-50%, “3” 50-75%, and “4” represents 75-
100% appear lysed and shriveled.  A “+/-“ is used to signify the upper and lower limits of 
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each range.  Results were tallied in a Microsoft Excel® spreadsheet.  When cells reached 
a level of “3/3+,” tubes were frozen at -70°C for harvest.  If CPE was insufficient (<3) 
after one week post-inoculation, an additional 2ml EMEM was added to the culture tube 
which was then returned to the incubator.  Cells were frozen for passage if CPE was < 3 
two weeks post-inoculation or non-viral induced cell deterioration were observed.  
Passages were performed in the same manner as inoculations using 200µl inocula. 
Nucleic Acid Extraction    
 Total RNA was isolated from cells using a Qiagen® RNeasy MiniKit (Valencia, 
CA; catalog # 74104).  Cell culture supernatants (140µl) were lysed in 350µl Buffer RLT 
and 350µl 70% ethanol.  Lysates were transferred to RNeasy spin columns and 
centrifuged at 10,000 x g for 1min.  Columns were washed successively with 700µl 
Buffer RW1 and 500µl Buffer RPE with centrifugation between each wash.  Viral RNA 
was eluted from spin column membrane in RNase-free water. 
Elution volumes were either 100µl or 35µl.  This depended on both the amount of 
RNA required for subsequent analysis and the desired final concentration.  RNA used for 
RT-PCR assay comparisons was eluted in 100µl water because multiple amplifications 
were required.  RNA extracted solely for sequencing was eluted in 35µl water to yield a 
more concentrated product and facilitate sequence analysis (see below). 
Nucleic Acid Amplification 
 RNA was amplified using RT-PCR by either a one-step or two-step procedure, 
depending on oligonucleotide primer pairs.  Oligonucleotide primers were obtained from 
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Operon® (Alameada, CA) as lyophilized powders that were re-hydrated in 100µl RNase-
free water upon receipt.  Multiple 20µl aliquots of 100µM working solutions were 
prepared and stored at -20°C to eliminate excessive freeze/thaws of stock solution.  Six 
different primer sets were utilized and are summarized in Table 3 and Figure 5.  Qiagen® 
One-Step RT-PCR Kits (catalog # 210212) were used for five primer pairs.  A two-step 
RT-PCR system using Promega® Reverse Transcriptase (Madison, WI; catlog # M900A) 
and Fisher Scientific® Taq Polymerase (Fair Lawn, NJ; catalog # FB60045) was used for 
one primer set.  All temperature cycling was performed in a Perkin Elmer® PE9700 
thermal cycler.  Master mix components and thermal cycler profiles are included in 
Appedndix I.   
 Five different oligonucleotide primer pairs were analyzed as candidates for 
inclusion in a molecular serotyping protocol to be implemented at FL DOH – Tampa.  
Two of these primer sets were developed by Dr. Steven Oberste and his colleagues at 
CDC (59,64).  These primer sets (Oberste  “A” and “B”) were used in conjunction with a 
Qiagen One-Step RT-PCR kit.  The Casas primer pairs (referred to as “1st” and “2nd”) 
were designed to be used in a nested assay that is stated to be capable of producing 
“sequencable” amplicons from clinical samples (15).  The ability to identify virus identity 
directly from clinical specimens could eliminate the need to isolate the virus in culture, 
leading to significant savings in both expense and “turnaround time.”  These two primer 
pairs were used both alone and in nested amplification reactions with Qiagen One-Step 
RT-PCR reactions.  The final primer set, Caro, consisted of six oligonucleotides, which 
were used in a two-step reaction.  Despite numerous attempts, the Caro primers failed to 
produce correctly-sized amplicons with the Qiagen One-Step RT-PCR kit.   
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Cell culture, extraction, and amplification negative controls were included in all 
experiments.  All assays were validated prior to comparison by demonstrating the ability 
to amplify several common serotypes and produce intense bands on agarose gels.  
Annealing temperature optimization experiments were initiated, but abandoned due to the 
necessity of a relatively low annealing temperature (~42°C) required with deoxyinosine 
bases (60). 
Table 4: Oligonucleotide Primer Sets 
Primer Sequence (5’ → 3’) Name (Reference) Amplicon Length  
ENT3 CCTCCGGCCCCTGAATG Screening (88) 196bp 
ENT4 ACCGGATGGCCAATCCAA   
222 CICCIGGIGGIAYRWACAT Oberste A 338bp 
292 MIGCIGYIGARACNGG   
012 ATGTAYGTICCICCIGGIGG Oberste B 450bp 
040 ATGTAYRTICCIMCIGGIGC   
011 GCICCIGAYTGITGICCRAA   
VP1-1A TGIGGAYTGRTAYCTIKYKGGRTARTA Casas 1st (15) 803bp 
VP1-1S GGTTYGAYITGGARITIACITTYGT   
VP1-2A CCIGTKKWRCAAIYYRCAYCTIGC Casas 2nd (15) 609bp 
VP1-2S ARWTWATGTAYRTICCICCIGGIG   
EUC2 TTTGCACTTGAATATGTA 1452bp 
EUC2a GGTTCAATACGGCATTTGGA 
Caro (14) 
  
EUC2b GGTTCAATACGGTGTTTGCT  
EUG3a TGGCAAACTTCCWCCAACCC 
 
 
EUG3b TGGCAAACATCTTCMAATCC   
EUG3c TGGCAGACTTCAACHAACCC   
Standard IUB Ambiguity codes used. 
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Figure 5: VP1 Amplicon Locations 
  
Location of amplicons shown.  Primers anneal to the flanking sides.  Lines represent five expected 
amplicons from the VP1 assays used.  “Screening” primers, which anneal to the 5’NTR, are not shown.  
   
Detection and Sample Preparation for Sequencing 
 All RT-PCR products (10-20µl) were visualized via gel electrophoresis.  One 
percent agarose gels (0.435g NuSieve agar, 0.215g SeaKem agar, 65ml 1X TAE) were 
utilized, each containing 5µl 0.1% ethidium bromide.  Electrophoresis was conducted at 
125mV for approximately fifty minutes with 5µl lane marker (Promega, catalog # 
G316A) used in each gel to ensure that products were of the expected size.   
QIAquick Gel Excision kits (Qiagen, catalog #28706) were used to “clean-up” 
amplification products.  Bands to be sequenced were excised with a scalpel, which was 
washed with 10% bleach and 70% ethanol between each use to prevent cross-
contamination.  Bands were placed in 1.5ml Eppendorf tubes and weighed using an 
analytical balance.  Bands were re-suspended in GC Buffer at a 3:1 buffer volume : band 
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mass ratio.  Dissolved bands were transferred to spin columns, washed with PE Buffer, 
and centrifuged in microcentrifuge at 20,000 x g for 2 minutes.  Nucleic acid was eluted 
from filter by the addition of 30µl Buffer EB and subsequent centrifugation at 8,000 x g.   
These products (5µl) were analyzed on a second 1% agarose gel along with 2µl 
and 4µl lane marker in order to provide a rough estimate of dsDNA concentration.  One 
µl lane marker contains roughly 7ng dsDNA.  Between 5ng and 20ng are required for 
sequencing.  By comparing the band intensity of the “clean-up” product to that of the two 
lane markers it is possible to estimate the amount of dsDNA present.  This “quasi-
quantification” step is crucial to determine the amount of template to add to the 
sequencing reaction.  Insufficient or excess quantities of dsDNA will adversely affect the 
sequencing reaction. 
Nucleotide Sequencing 
 Nucleotide sequencing of RT-PCR amplicons was performed with a Beckman-
Coulter® (Fullerton, CA) CEQ8000 Automated Sequence Analysis System in accordance 
with manufacturer’s protocol.  It should be noted that although the enteroviruses are 
ssRNA viruses, it is the RT-PCR dsDNA amplicon that is being analyzed.  Therefore 
DNA, not RNA, is sequenced.  Briefly, this instrument uses the Sanger method of dye-
terminators incorporated into an enzyme-mediated amplification reaction.  Bases with 
these dye-terminators effectively halt polymerization in a PCR-like reaction.  Linear 
products of varying lengths (ranging from 1 to n, where n is the length of the amplicon) 
are obtained.  This product is precipitated and loaded onto the instrument whereby it is 
passed through a poly-acrylamide gel and separated based on size.  A laser within the 
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instrument detects the wavelength of each dye and makes a “base call.”  Each dye is 
covalently-linked to a specific base [black = G, red = T, blue = C, green = A].  Software 
computes the sequence, based on user-supplied parameters, which can then be exported  
and stored in a database.  
 Sequencing reactions were carried out using DTCS Quick Start kits (Beckman-
Coulter, catalog # 608126).  Twenty µl reactions were prepared in either 48- or 96-well 
plates.  Thermal cycling was performed in a PE9700 thermal cycler.  Appendix I includes 
master mix components and thermal cycling profile.  Glycogen (20mg/mL), 3M Sodium 
Acetate, and 100mM EDTA were combined in a 1:2:2 ratio.  Five µl of this “stop 
solution” were added to all wells to ensure product extension was terminated.  Well 
contents were then ethanol-precipitated to remove salts and other debris.  One wash was 
performed with cold (-20°C) 95% ethanol prior to centrifugation at 6,000 x g for 5 
minutes.  Two additional washes with cold (-20°C) 70% ethanol and two centrifugations 
at 6,000 x g for 3 minutes were performed.  Forty µl SLS solution (included with DTCS 
Quick Start kit; SLS is a de-ionized formamide solution) was added to each well.  After 
10 minutes incubation at room temperature, plates were vortexed lightly and each well 
was overlayed with mineral oil.  Plates were added to instrument and run was initiated.  
Method LFR (long fragment read) was used for all runs. 
Sequence Analysis 
 Sequence data was exported to the SeqmanII module of the Lasergene software 
suite (DNAStar, Madison, WI) in the form of a “.scf” file.  These files contain not only 
the analyzed data (“base calls”), but the raw sequence data as well (“ferragrams”).  The 
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SeqmanII module is an assembly program that allows the assembly of contigs, which are 
consensus sequences derived from bi-directional sequencing using both the forward and 
reverse Oberste A primers, 292 and 222 respectively.  This provides a level of quality 
control and allows for better coverage of the amplicon region.  Assembled contigs were 
saved as “.seq” files which can be used in all modules of Lasergene. 
 Two methods were compared for sequence alignment, both of which utilize the 
Clustal W (slow/accurate option) algorithm.  One of these, Megalign, is included within 
the Lasergene suite.  The other is located on a freely available, web-based application 
(URL: http://searchlauncher.bcm.tmc.edu/multi-align/multi-align.html).  These are both 
progressive pair-wise alignment algorithms, which attempt to align homologous bases 
and insert gaps where homology is not present [Note: The Oberste method developed at 
CDC uses a more sophisticated alignment algorithm, however, it requires a dedicated 
UNIX-based server and a $20,000+ software package].   
Alignments were used to create phylogenetic trees.  Again, two methods were 
compared.  The Megalign module automatically constructs a phylogenetic tree when an 
alignment is produced.  Another freely-downloaded software program, MEGA 
(molecular evolutionary genetic analysis), was also used.  This program is available at 
URL: http://www.megasoftware.net/.  The MEGA program allows the user to specify 
preferences, while the Megalign module does not.  A neighbor-joining tree was used 
because, unlike the UPGMA (Unweighted paired group mean arithmetic) tree option, a 
constant rate of evolution is not assumed.  This is the more appropriate model for RNA 
viruses because the rate of evolution is not constant and, in fact, differs considerably 
among different genomic regions (of the same virus) due to variation of selection 
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pressures (23).  Phylogenetic trees from both methods were evaluated for accuracy of 
branch points and phyletic clusters. 
The use of basic local alignment search tool (BLAST) searches to identify 
enterovirus serotypes was also evaluated.  BLAST utilizes an NIH-supported, freely 
available sequence database (located at the following URL: 
http://www.ncbi.nlm.nih.gov/BLAST).  Briefly, this program compares any sequence 
data (nucleotide or protein) against an enormous database that is maintained by the 
National Library of Medicine, commonly referred to as GenBank.  Sequences obtained 
were queried against GenBank and evaluated for accuracy.
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Results 
Specific Aim #1 (Descriptive Epidemiology) 
 Enteroviruses have been routinely isolated at the Florida Department of Health – 
Tampa Laboratory (FL DOH – Tampa) in the past several decades.  Submission of 
samples for diagnostic culture has resulted in the isolation of over two thousand 
enteroviruses since 1981.  The laboratory has been engaged in virus isolation since the 
1960s; however, data was unavailable for years prior to 1981.   
 The distribution of serotypes isolated at FL DOH - Tampa is representative of 
national trends.  A total of fifty serotypes were isolated (fifty-five if the re-classified E8, 
E10, E22, E23, and E34 are counted).  The CBVs were isolated somewhat frequently.  
Other serotypes isolated quite regularly included: CA9, E6, E7, E9, E11, E30, and E31.  
The PVs were isolated quite often, but this is not indicative of the prevalence of illness.  
Inoculation with the Sabin, live-attenuated vaccine led to most (if not all) of these viral 
isolates.  The three non-pathogenic PV strains readily propagate in cell culture, but do not 
usually cause human illness.  Figure 6 shows the distribution of enterovirus serotypes 
isolated at FL DOH – Tampa since 1981.   
 The distribution of serotypes isolated is inherently biased.  Isolates causing more 
serious illnesses will tend to be over represented.  Obviously, asymptomatic infections 
will not result in viral isolations because specimens will not be submitted.  Also, the ease
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with which serotypes replicate in vitro will skew isolate distribution.  This is evident by 
the high number of CBV isolates and the low number of higher numbered CAVs and 
echoviruses.  Enteroviruses were numbered chronologically, therefore, it follows that the 
higher numbered serotypes may often be more difficult to isolate and identify.  Echovirus 
30 is a notable exception, but its higher rate of isolation is likely due to its frequent 
association with meningitis. 
Figure 6: Serotype Distribution 
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The distribution of enterovirus serotypes isolated at FL DOH – Tampa, 1981-2002 (humans only).  
Serotype determined by serum neutralization.  Serotypes not represented indicate no isolations over the 
time period. E10, E22, E23, and E34 are included since they were still considered unique serotypes at the 
time of isolation.  E22/E23 represents samples that could not be differentiated due to their similar 
characteristics.  
 
Enterovirus isolation has been a significant portion of the workload at FL DOH – 
Tampa between 1981 and the mid 1990’s.  Between 1981 and 2002 an average of just 
under ninety-eight enteroviruses were isolated per year.  From 1989-1991 FL DOH – 
Tampa was involved in a research study that resulted in a large increase in specimen 
submission.  Since 1995, there has been a decrease in specimens submitted for 
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enterovirus isolation.  This drop is almost certainly not a result of lower prevalence and 
several explanations are described in the following section.  Figure 7 shows the number 
of enterovirus isolations by year.  Enteroviruses have been isolated from nearly fifteen 
percent of all non-herpes diagnostic viral isolation specimens since 1981.    
Figure 7: Enterovirus Isolations by Year 
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Enteroviruses isolated at FL DOH – Tampa, 1981-2002.  The large increase in isolations from 1989-1991 
corresponds to years that the laboratory was involved in a research study evaluating septic systems.  This 
was a prospective study comparing enterovirus isolations from asymptomatic patients in two groups, as 
defined by type of water treatment. 
 
Figure 8 depicts enterovirus isolations as a percent of all non-herpes virus 
isolation diagnostics at FL DOH - Tampa.   Specimens positive for enteroviruses are 
primarily stool or CSF (which are the clinical standard).  It is quite common to obtain 
both stool and CSF from the same patient.  At least seventy-five percent of all 
enteroviruses isolated were from these two types of specimens.  Figure 9 displays the 
large variety of specimen types from which enteroviruses have been isolated at FL DOH 
– Tampa.  Seasonality of enterovirus isolation is depicted in Figure 10.  July through 
November appears to be the height of “enterovirus season” in Florida, although 
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September had lower totals.    
Figure 8: Enterovirus Diagnostic Isolations 
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Figure 8 shows enterovirus isolates as a percentage of all human diagnostic results at FL DOH – Tampa, 
1981-2002.  Includes virus isolation samples submitted during the time period, excluding herpes samples.  
 
Figure 9: Specimen Submission by Type  
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Specimen types from which enteroviruses were isolated (N=2150) among specimens submitted for virus 
isolation to FL DOH – Tampa, 1981-2002.   
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Figure 10: Enterovirus Isolation by Month 
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Enterovirus isolation totals for each month (based on date of serum neutralization assay results) at FL DOH 
– Tampa, 1981 – 2002. 
 
Specific Aim #2 (RT-PCR Assay Comparison) 
 Relative to the standard screening assay, none of the VP1 assays (Oberste A/B, 
Casas 1st/2nd/Nested, Caro) performed as well in detecting the presence of enterovirus 
RNA.  Specificity and positive predictive value (PPV) were all 100% because the panel 
of isolates used was all (originally classified as) enteroviruses.  Only two isolates 
(Reovirus and Hepatitis A) did not amplify with the “screening” primer set, which 
anneals to the highly conserved 5’NTR region, and none of the five VP1-annealing 
primer sets amplified any of these samples.  Therefore, sensitivity and negative 
predicative value were more indicative of utility since these values did exhibit variation.  
Figure 11 illustrates the predictive values of each primer set.  Clearly, the performance of 
the Oberste A oligonucleotide primer set was superior to the others.  This primer set had 
the highest sensitivity (85.18%) and highest NPV (20.00%).  Only one isolate (PV3) was 
amplified with another VP1 primer set that failed to amplify with the Oberste A set.  
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Table 5 shows a side-by-side comparison of all RT-PCR results from the enterovirus 
panel and the two-by-two tables are included in appendix II.     
Figure 11: RT-PCR Assay Comparison 
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Predictive values obtained from 2 x 2 tables relative to “screening” assay.  Each primer set was used to 
amplify RNA from a panel of fifty-six virus isolates.  The “screening” primers anneal to the highly-
conserved 5’NTR and amplify virtually all enterovirus serotypes.    
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Table 5: RT-PCR Results  
 Virus S OA OB C1 C2 CN R Virus S OA OB C1 C2 CN R 
CA2 + + - - - - # Reo - - - - - - - 
CA3 + + + - - - + E11 + + + + - # + 
CA4 + - - - - - - E11' + # + + - # + 
CA5 + + + - - - - E12 + + - + + + - 
CA6 + + - - - - - E13 + + + + + + # 
CA7 + + + + - - + E14 + + + - - - # 
CA8 + + + - - + # E15 + # + + - - + 
CA9 + + + + - - + E16 + + # - + + - 
CA10 + - - - - - # E17 + + + + + + + 
CA13 + + # # - - # E18 + + + - + + + 
CA14 + + + + - - - E19 + + - + - - + 
CA16 + - # # # - - E20 + + + + + # + 
CB1 + + + + - - # E21 + + - + - - + 
CB2 + + + - - - # E22 + - - - - - - 
CB3 + + - - - - - E23 + + + - # - + 
CB4 + + - - - - # E24 + + + - - - + 
CB5 + + - + - + # E25 + # # + - + - 
CB6 + + + - + - + E27 + + + + + + - 
E1 + + # - - - - E30 + + + + - + + 
E2 + + + # + + + E31 + - - - - - - 
E3 + + - + - - # E33 + + + - - - - 
E4 + + + + + + + EV68 + - - - - - - 
E5 + + + + # + + EV70 + # - # - - - 
E6 + + + + + + + EV71 + - - - - - - 
E6" + + # + - - + HAV - - - - - - - 
E7 + + + + # - + P1 + + + - - - - 
E8 + + + - - - # P2 + + - + - + + 
E9 + + + + + + + P3 + - - + - + - 
Notes: A = Oberste A; OB = Oberste B; C1 = Casas 1st; C2 = Casas 2nd; CN = Casas Nested; R = Caro;  
S = Screening  + = strong positive; # = weak positive; - = negative 
 
Specific Aim #3 (Sequence Analysis) 
 Nucleotide sequencing was attempted with all amplicons obtained from RT-PCR 
with the Oberste A primer set (N=46).  Sequence results were obtained from forty-three 
amplicons (93.47%).  Of these forty-three sequences, thirty-four (79.07%) correctly 
matched the original SN data.  The nine that were discrepant were submitted to CDC for 
confirmatory analysis.  All molecular results obtained at FL – DOH concurred with CDC 
analysis.  Several possibilities for this apparent discrepancy are explored in the next 
section.   
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 BLAST scores above 165 and E-values below e-40 are quite reliable for 
enterovirus typing based on observations obtained in this study assuming only the highest 
score is used.  Often several serotypes will match at varying scores.  The output of 
BLAST generates a list of possible matches (referred to as “hits” in the module) based on 
the query sequence.  This output gives a graphical depiction of the alignment, a score, 
and an e-value.  A graphic is provided depicting the alignment of the user-supplied query 
sequence and where it matches to the GenBank database sequence.  Alignments with 
large interruptions (gaps) should be acknowledged with skepticism.  The score is 
computed based on the length of the alignment and the absence of gaps.  Thus, the higher 
a score is, the better the match.  The e-value represents the odds that a given match could 
have occurred by chance.  Consequently, as “E” approaches zero, the confidence in the 
match approaches 100%.   
The alignment can also be viewed “base-by-base.”  This base-by-base match 
percentage should be used cautiously because this percentage does not incorporate gap 
lengths or length of alignment.  For example, the CA8 query sequence aligned with 
87.8% homology to the GenBank CA8 sequence, but the score was only 76; the 
alignment was only 65/74 bases.  Table 6 depicts Blast results obtained in this study.      
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Table 6: BLAST Results  
DOH SN Isolated Length BLAST Score E-Value Match % CDC ID
CA10 1991 337 CA10 494 1.00E-138 285/297 96.00% CA10 
CA14 1987 330 CA4 363 1.00E-97 279/311 89.70% CA4 
CA2 1990 320 CA2 165 9.00E-40 243/297 81.80% CA2 
CA3 1986 314 CA3 248 7.00E-65 258/302 85.40% CA3 
CA5 1981 N/A N/A N/A N/A N/A N/A N/A 
CA6 1978 302 CA10 482 1.00E-135 276/287 96.20% CA10 
CA7 1982 336 CB2 478 1.00E-134 287/302 95.00% CB2 
CA8 1991 305 CA8 76 8.00E-13 65/74 87.80% CA8 
CA9 1993 341 CA9 299 3.00E-80 289/335 86.50% CA9 
CB1 1995 309 CB1 363 1.00E-97 216/227 95.20% CB1 
CB2 1995 353 CB2 402 1.00E-111 105/339 90.00% CB2 
CB3 1994 292 CB3 424 1.00E-118 262/278 94.20% CB3 
CB4 1993 321 CB4 422 1.00E-115 274/293 93.50% CB4 
CB5 1992 318 CB5 502 1.00E-141 283/293 96.60% CB5 
CB6 N/A 348 CB6 640 0 326/327 99.70% CB6 
E1 1993 330 E8 186 3.00E-46 269/326 82.50% E8 
E11 1992 347 E11 607 1.00E-172 330/338 97.60% E11 
E11' 1989 325 E11 509 1.00E-143 307/321 95.60% E11 
E12 1989 325 E12 192 5.00E-48 244/293 83.30% E12 
E13 1985 319 E13 194 6.00E-47 254/306 83.00% E13 
E14 1992 321 E14 204 7.00E-50 256/307 83.40% E14 
E15 1990 N/A N/A N/A N/A N/A N/A N/A 
E16 1991 356 E16 288 9.00E-77 290/339 85.50% E16 
E17 1983 274 E17 406 1.00E-112 262/278 94.20% E17 
E18 1994 326 E18 474 1.00E-131 299/319 93.70% E18 
E19 1987 315 E19 256 4.00E-67 219/249 88.00% E19 
E2 1990 357 E2 232 7.00E-60 285/341 83.60% E2 
E20 1990 322 E30 603 1.00E-171 316/321 98.40% E30 
E21 1994 319 E21 392 1.00E-108 276/302 91.40% E21 
E23 1987 360 E30 628 1.00E-177 336/341 98.50% E30 
E24 1981 330 E30 571 1.00E-162 306/311 98.40% E30 
E25 1991 358 E25 246 2.00E-62 275/324 84.90% E25 
E27 1991 316 E9 347 7.00E-93 277/324 85.50% E9 
E3 1993 328 E3 543 1.00E-152 301/310 97.10% E3 
E30 1993 326 E30 591 1.00E-168 310/314 98.70% E30 
E33 1984 327 E30 551 1.00E-156 306/314 97.50% E30 
E4 1988 N/A N/A N/A N/A N/A N/A N/A 
E5 1994 359 E5 287 6.00E-75 286/333 85.90% E5 
E6 1994 311 E6 198 8.00E-50 260/312 83.30% E6 
E6" 1989 327 E6 299 3.00E-80 61/70 87.10% E6 
E7 1993 337 E7 577 1.00E-163 315/323 97.50% E7 
E8 1973 313 E8 174 8.00E-42 229/276 83.00% E8 
E9 1994 319 E9 315 3.00E-83 273/307 88.90% E9 
EV70 1988 348 E9 337 2.00E-91 296/338 87.60% E9 
P1 1991 316 P1 545 1.00E-154 295/299 98.70% P1 
P2 1990 356 P2 662 0 337/338 99.70% P2 
  44 
 
 
 
 
 This method of analysis has correctly identified several isolates this year at FL 
DOH – Tampa.  Two College of American Pathologists performance evaluation samples 
(VR9 and VR11) were identified as CB5 and E11, respectively, in concordance with SN 
results.  Two recent clinical diagnostic isolates were correctly identified as E9, which 
again corresponded to SN results.  An additional sample, which had been indeterminate 
via SN, was determined to be an E9 isolate. 
 Examination of the phylogenetic tree produced by Megalign for the isolates used 
in this study reveals several key relationships.  For the most part, the alignments appear 
to be accurate relative to published data.  Due to varying lengths of sequences obtained, a 
287bp segment was examined.  All fourteen CB5 isolates cluster together [note: CB5 and 
clinical-n are the same sequence].  Both of the recent diagnostic samples, clinical-a and 
clinical-b, cluster with E9, as do the erroneous, according to BLAST results, E27 and 
EV70.  The cluster of CA7 with CB2 also concurs with BLAST results.  The E30 cluster 
contains E20, E23, E24, and E33, again confirming BLAST results.  Finally, the parings 
of CA6 with CA10 and CA14 with CA4 also support BLAST results.  Thus, the 
phylogenetic tree supports the BLAST results that are discordant with the SN data.  The 
homologous serotypes E1/E8, E6/E6”, and E11/E11’ all cluster tightly with one another.  
The HEV-A, HEV-B, and PV species branch at appropriate locations.  The HEV-C and 
HEV-D species (higher numbered CAVs and EV68/EV70) are not represented among the 
isolates assayed. 
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Figure 12: Megalign Phylogenetic Tree  
Phylogenetic tree created in Megalign of a secondary alignment of 287 bases created from initial alignment 
in order to correct for variation in sequence lengths. 
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The phylogenetic tree produced with ClustalW and MEGA was quite similar to 
that obtained with the Megalign module.  No secondary alignment was necessary because 
the MEGA software program does not count gaps in its similarity analysis.  Thus, 
sequences of varying lengths can be readily compared for relatedness.  The three species 
(HEV-A, HEV-B, PV) branched in the same manner as the Megalign tree.  All of the 
CB5 isolates clustered tightly with one another.  The discordant results clustered in the 
same patterns.  E70 and E27 clustered with E9, while E20, E23, E24, and E33 clustered 
with E30.  The three homologous pairs (E1/E8, E6/E6”, and E11/E11’) again grouped 
with one another.  Some slight differences were observed.  For instance, E17 branched 
with E18 off the E9 cluster, while it had been an orphan branch between HEV-B and PV 
in the Megalign tree.  Also, CA9 branched off of the CB5 cluster rather than from E7.    
These differences are likely due to differences in the algorithm used to construct the tree.   
 Published results of VP1 phylogenetic analyses suggest that portions of both trees 
are correct.  CA9 should cluster most closely with E7, E19 E11, and E11’, which is 
observed with the Megalign (but not the MEGA) tree (61).  On the other hand, E17 
should cluster most closely with E18, which is observed with the MEGA (but not the 
Megalign) tree (64).  Without sufficient replicates of each serotype (as in the CB5 
isolates) it is impossible to determine which phylogenetic tree most closely resembles the 
exact genetic relationship of these serotypes.  Finally, the inclusion of sequence data from 
the fifteen serotypes not represented in this study would greatly enhance the accuracy of 
both trees. 
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Figure 13: MEGA Phylogenetic Tree  
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Thirteen CB5 isolates, originally isolated between 1985 and 1992, were 
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sequenced and aligned using the Megalign module.  Similar studies have been conducted 
using as few as seven isolates (43).  A performance evaluation sample from 2003 (VR9) 
was included in the analysis as a reference.  Due to varying lengths of sequences 
obtained, a 256bp segment was examined for overall homology.  Similarity indexes 
among the thirteen DOH isolates ranged from 91.4% and 98.8%.  Interestingly, the VR9 
isolate (whose BLAST and SN results indicate CB5 serotype) was only between 75.8% 
and 77.7% similar to the thirteen DOH isolates.  It is probable that this is the prototype 
strain and does not reflect the divergence that has occurred since its initial isolation in the 
1950’s.  There were 12 C→A substitutions, 38 G→A substitutions, 8 T→A substitutions, 
3 G→C substitutions, 62 T→C substitutions, and 6 T→G substitutions. The higher totals 
for G→A and T→C are expected since purine-purine and pyrimidine-pyrimidine 
substitutions are more readily tolerated due to similar structures.  The entire alignment 
report of the clinical isolates is shown in Appendix II.  
 Ten serial passages of E9 were performed to examine the sensitivity of the 
sequencing analysis and to determine how frequently mutations occur in vitro.  The 
relatively high error frequency of the enterovirus RNA polymerase coupled with the 
bottle neck effect of sequential passages was expected to produce numerous base 
substitutions.  Due to varying lengths of sequences obtained, a 259bp segment was 
examined for overall homology.  Only one base change was observed, an A-G 
substitution after the third passage.  Figure 14 shows a portion of the alignment report for 
the ten passages. 
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Figure 14: Portion of E9 Passage Alignment 
Portion of the alignment report created in Megalign from 10 sequential passages of an E9 isolate.  The A-G 
transition (which occurred between the third and fourth passages) is seen at position 201 of the alignment. 
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Discussion 
Enterovirus infections produce serious illness throughout the world and 
surveillance for them should be an important function of public health laboratories.  The 
“gold standard” assay for identification of enteroviruses has considerable drawbacks.  
The test is labor intensive, requires long “diagnostic lags,” and often fails to yield 
conclusive results.  Due to these and other factors, specimen submissions to FL DOH – 
Tampa for enterovirus isolation and identification have dropped dramatically in recent 
years.  By no means, however, should this be interpreted as a decrease in either 
prevalence of enteroviral illness or transmission. 
 The workload in the virology section of FL DOH – Tampa has evolved in the past 
several years.  West Nile Virus, Norovirus, and Herpesvirus testing has soared in recent 
years.  For instance, between 1997 and 2002, over 1700 specimens (49.76% of diagnostic 
virus isolation submissions) were determined to be positive for Herpesvirus via 
diagnostic virus isolation.  Yet, between 1981 and 1996, less than 200 specimens (1.31% 
of submissions) were positive using the same assay.  The advent of commercially 
available molecular reagents and kits has transformed virology labs across the country.  
This is evident at FL DOH – Tampa, where molecular assays for West Nile and 
Norovirus detection have been added since 1999.  Currently, Influenza and SARS 
surveillance are also being conducted using molecular methods.  These assays are 
performed not only as clinical diagnostics, but also to provide surveillance data.  Clearly, 
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public health laboratories are dynamic institutions that must be capable of responding to 
the needs of the citizenry.   
 Perhaps one of the biggest factors involved in the considerable decrease in 
enterovirus diagnostic specimens at FL DOH – Tampa is the turnaround time for 
reporting of results.  To isolate and identify an enterovirus takes at least two weeks even 
under optimal circumstances.  This assumes:  
• A sample is received late in the week and appropriate culture tubes 
(BGM/RMK/MRC-5) are available.  
• The specimen produces CPE within one week so that the titration and serum 
neutralization can be performed the following Friday 
• No cross-neutralization occurs and the SN results are unambiguous. 
• The enterovirus is one of the forty-two serotypes included in the WHO anti-sera 
pools 
The use of monotypic anti-sera to individual serotypes allows identification of the 
remaining twenty-two serotypes, but adds considerable time and cost to the procedure.  
The presence of mixed serotypes, aggregation of virus particles, and the use of multiple 
passages to produce CPE can (and often do) affect the outcome of the SN assay. When 
such complications arise the turnaround time can easily increase to well over one month.  
At this point, the diagnosis is of little clinical utility.  Often clinicians simply do not 
bother to order the test. 
 Several other factors also help explain the decrease in enterovirus specimen 
submission in recent years.  The re-classification of meningitis to a “non-reportable” 
disease is likely responsible for at least a portion of the decline.  Lack of treatment 
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options renders the determination of serotype a moot point in the minds of many 
clinicians.  The reasoning being, “why order a test if the result will not affect patient 
outcome?”  Health insurance companies may not reimburse for such tests using the same 
logic.   
 From a public health standpoint, it makes sense to be able to identify enterovirus 
serotype accurately and quickly.  Outbreaks of EV71 (hand-foot-and-mouth-disease) in 
Southeast Asia and E30 (meningitis) throughout Europe and the Americas demonstrate 
the ability of the enteroviruses to produce significant morbidity and mortality.  Early 
recognition of infection patterns allows a more rapid and effective public health response. 
 This thesis evaluated several molecular protocols capable of identifying 
enterovirus serotype.  Amplicon sequencing of RT-PCR products of the VP1 region of 
the enterovirus genome has been demonstrated as a reliable method of identifying 
enteroviruses.  The nucleotide sequence of the VP1 region correlates highly with serotype 
because a large percentage of neutralization sites are located on the VP1 portion of the 
enterovirus capsid.  The Oberste A oligonucleotide (292/222) exhibited the best overall 
performance.  When compared to the screening assay (which is highly sensitive and 
specific, but produces an amplicon whose nucleotide sequence does not correlate with 
serotype) this primer set produced higher sensitivity and higher negative predictive value 
than all other VP1 primer sets.  Subsequently, these amplicons were sequenced and 
evaluated for their ability to predict serotype.   
 Of the fifty-four serotypes amplified by the screening primers, forty-six amplified 
with the Oberste A primers (85.19%).  The E22 isolate was not expected to amplify, but 
the other seven negatives may be a result of individual strain variability, because the 
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Oberste A primer set has been reported to be capable of amplifying all prototype strains 
(64).  Forty-three sequence results were obtained (93.48%) with these primers.  Two 
isolates, E4 and E15, produced only very faint bands via gel electrophoresis in three 
separate attempts; thus, amplicons were “unsequencable.”  Another isolate, CA5, produce 
a very intense amplicon with a secondary band slightly above it (~550bp).  Nucleotide 
sequencing yielded a “peak-under-peak” ferragram, which is characteristic of multiple 
templates.  Therefore, the CA5 isolate may actually be a combination of multiple 
serotypes, which was not revealed in the initial SN assay. 
 Overall, there was good correlation between sequencing results and SN results.  
Thirty-four of the forty-three (79.07%) sequencing results yielded equivalent results 
when BLAST searches were employed.  The use of BLAST searches to identify serotype 
seems to be a useful and reliable method for identifying enteroviruses.  Construction of 
phylogenetic trees yielded slightly different results when two tree creation algorithms 
were employed.   
Discrepant results were repeated (re-extraction of original isolate, new RT-PCR, 
new sequencing) and sequences were sent to CDC for confirmation.  Results reported 
reflect those obtained from the second analysis.  Confirmation by CDC concurred with 
molecular results, not SN, in all cases.    
Of the results in which a discrepancy arose, several explanations are possible.  
Contamination is always a possibility when performing molecular assays.  However, cell 
culture, extraction, and amplification negative controls all performed as expected.  If 
contamination were the source of error it would be expected that only one or two 
serotypes would be represented, not five (E30, CA10, CB2, CA4, and E9).  In addition, 
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no divergence would be expected in the phylogenetic trees (as in CB5 and clinical n, 
which are the same sample).  The SN-determined EV70 isolate clustered most closely 
with E9, while in published results EV70 should have branched separately from all 
isolates used in this study due to its membership in the HEV-D species (71).   
It is possible that the initial SN results were inaccurate, archive records were 
mislabeled, or these isolates were actually multiple serotypes but when resurrected from 
archive and passaged, one serotype propagated preferentially.  One isolate, E23, was 
almost certainly archived incorrectly.  The CPE was observed in BGM culture was not 
consistent with that expected for E22/E23.  Furthermore, the VP1 region in these two 
Picornaviruses is highly divergent from other enteroviruses and amplification should not 
have occurred with any of the VP1 oligonucleotide primers.  A CDC official states that 
the discrepancy between SN and molecular results is “not surprising” (60).  Time 
limitations prevented these nine isolates from being “re-serotyped” using the serum 
neutralization assay at FL DOH - Tampa.  Despite these discrepancies, the advantages of 
using sequencing in place of serum neutralization cannot be denied. 
Nucleotide sequence data provides a wealth of data that could be used in 
molecular epidemiology studies in the future.  Results of both the CB5 isolate alignment 
and the E9 passage experiment demonstrate the utility of sequence data.  The thirteen 
CB5 isolates obtained were shown to be closely-related to one another, yet quite 
divergent from the performance evaluation sample (prototype CB5 strain).  It is quite 
possible that CB5 strains circulating in Florida are divergent from CB5 strains in other 
areas.  The bi-directionality of nucleotide substitutions with respect to time likely 
indicates that multiple strains are present which evolve independently.  A directional 
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change in base substitutions with respect to time would have indicated a continually 
circulating CB5 strain.  Although amino acid sequence analysis was not conducted (as it 
was beyond the scope of this project), it would be of interest to examine which base 
substitutions resulted in codon changes.  Sequence analysis provides a means of 
analyzing intra-serotypic variation that is simply not possible wit the serum neutralization 
assay. This is evident in the next experiment, although conservation, not divergence, is 
observed.   
The E9 passage experiment demonstrates both the accuracy of sequencing and the 
inherent stability of viruses cultured in vitro.  Only one substitution was observed in the 
amplicon across ten passages.  All sequence data aligned perfectly demonstrating the 
robustness of sequence analysis, i.e. the same sequence (not including the substitution) 
was obtained from all ten isolates.  Due to the high error rate of the enterovirus RNA 
polymerase, it was expected that more substitutions would have occurred.  Perhaps the 
amplicon sequence under investigation is involved in receptor recognition and/or binding 
and, thus, is conserved.  It is also possible that the passages required to produce 
consistent, strong CPE (five) produced a strain that was uniquely adapted to in vitro 
culture.  However, even if the both of the above were true some substitutions could be 
tolerated due to the degeneracy of the genetic code.  It is likely that ten passages simply 
was not enough to produce significant change in this portion of the enterovirus genome.  
After all, it took Albert Sabin hundreds of passages to produce the avirulent phenotypes 
of the three polioviruses used in the live, attenuated oral polio vaccine (50). 
These “mini experiments” do not yield any significant findings on their own; they 
actually raise many more questions than they answer.  However, it cannot be denied that 
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sequence data allows analyses to be performed that are simply not possible with serum 
neutralization. 
Aside from the direct benefits of a molecular-based serotyping protocol relative to 
serum neutralization, several intangible benefits exist.  Through the course of this study, 
Dr. Steven Oberste at CDC has offered guidance and support.  He has supplied copies of 
his protocol, offered “trouble-shooting” advice, and performed confirmatory analysis of 
results.  This enhancement of the working relationship between CDC and FL DOH – 
Tampa can only be viewed as an asset.  In addition, all reagents required to perform this 
assay are available commercially (Qiagen® or Beckman-Coulter®). 
Reagent cost to perform the sequencing assay was less than twenty dollars per 
specimen.  Considerable “hands on” technician time is required; roughly, six hours is 
needed to perform all tasks from harvest of CPE-producing cultures to sequence data 
analysis.  This is somewhat higher total time than the  “hands on” time required to 
perform the serum neutralization assay (approximately three hours).  These costs are 
tolerable when the benefits of a molecular-based approach are considered.  
The method described in this study could easily be incorporated into routine use 
at a public health virology laboratory.  With the purchase of an appropriate 
oligonucleotide probe, a real-time screening assay (using the 5’NTR primers) could be 
incorporated into diagnostic assays already performed for other viruses (West Nile, 
Influenza, St. Louis Encephalitis).  Such probes have been described in the literature 
(103).  Appendix IV provides an algorithm for implementing such a protocol. 
This study demonstrates that nucleotide sequencing of enterovirus isolates, 
coupled with BLAST searches, allows for accurate and time-effective identification of 
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serotype.  A thermal cycler, gene sequencer, and an Internet browser are the only 
hardware required.  Expensive software programs, while beneficial, are not required to 
accomplish serotype identification.  In 2003, this method has correctly identified all 
clinical isolates received, as well as two performance evaluation samples.  The archive 
holdings of enterovirus isolates at FL DOH – Tampa are extensive and a more complete 
database of VP1 sequences will be created.  This will provide the opportunity to carry out 
larger-scale molecular epidemiology studies, which are useful in public health outbreak 
surveillance.  The forty-eight to seventy-two hour “turn-around” time eliminates the 
diagnostic lag inherent with the serum neutralization assay.  The capability of performing 
enterovirus identifications faster and from a larger number of specimens will improve the 
infectious disease surveillance capabilities of the Florida Department of Health.
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Appendix I 
 
Master Mix Components 
Oberste A One-Step RT-PCR 
Component (Final Conc.) Volume Stock Conc. 
RNase-free H2O 12.275µl - 
5X Buffer 5µl - 
dNTPs 1µl 10mM total (2.5mM each) 
30pmol primer 292 0.3µl 100µM (100pmol/µl) 
30pmol primer 222 0.3µl 100µM (100pmol/µl) 
10U RNasin (RNase inhibitor) 0.125µl 40units/µl 
Enzyme Mix 1µl Proprietary 
Template 5µl - 
Total 25µl - 
 
Oberste B One-Step RT-PCR 
Component (Final Conc.) Volume Stock Conc. 
RNase-free H2O 11.975µl - 
5X Buffer 5µl - 
dNTPs 1µl 10mM total (2.5mM each) 
30pmol primer 040 0.3µl 100µM (100pmol/µl) 
30pmol primer 011 0.3µl 100µM (100pmol/µl) 
30pmol primer 012 0.3µl 100µM (100pmol/µl) 
10U RNasin (RNase inhibitor) 0.125µl 40units/µl 
Enzyme Mix 1µl Proprietary 
Template 5µl - 
Total 25µl - 
 
Casas 1st One-Step RT-PCR 
Component (Final Conc.) Volume Stock Conc. 
RNase-free H2O 12.275µl - 
5X Buffer 5µl - 
dNTPs 1µl 10mM total (2.5mM each) 
30pmol primer VP1-1A 0.3µl 100µM (100pmol/µl) 
30pmol primer VP1-1S 0.3µl 100µM (100pmol/µl) 
10U RNasin (RNase inhibitor) 0.125µl 40units/µl 
Enzyme Mix 1µl Proprietary 
Template 5µl - 
Total 25µl - 
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Casas 2nd One-Step RT-PCR 
Component (Final Conc.) Volume Stock Conc. 
RNase-free H2O 12.275µl - 
5X Buffer 5µl - 
dNTPs 1µl 10mM 
30pmol primer VP1-2A 0.3µl 100µM (100pmol/µl) 
30pmol primer VP1-2S 0.3µl 100µM (100pmol/µl) 
10U RNasin (RNase inhibitor) 0.125µl 40units/µl 
Enzyme Mix 1µl Proprietary 
Template 5µl - 
Total 25µl - 
 
Casas Nested One-Step RT-PCR 
First RT-PCR identical to Casas 1st; Second RT-PCR identical to Casas 2nd.  Product (5µl) of Casas 1st used 
as template for nested RT-PCR.  Dilutions performed ranging from 1:10 → 1:10,000, depending on 
intensity of amplicon obtained from first-round amplification. 
 
Caro Two-Step RT-PCR: RT 
Component Volume Stock Conc. 
10X Buffer 2µl - 
MgCl2 4µl 25mM 
dNTPs 8µl 10mM 
RNasin (RNase inhibitor) 0.25µl 40units/µl 
50pmol EUC2a primer 0.5µl 100µM (100pmol/µl) 
50pmol EUC2b primer 0.5µl 100µM (100pmol/µl) 
AMV RT enzyme 0.32µl 24units/µl 
Template 5µl - 
Total 20.57µl - 
 
Caro Two-Step RT-PCR: PCR  
Component Volume Stock Conc. 
10X Buffer 8µl - 
MgCl2 4µl 25mM 
RNase-free H2O 64.93µl - 
Taq polymerase 0.5µl 5units/µl 
50pmol EUC2 primer 0.5µl 100µM (100pmol/µl) 
50pmol EUG3b primer 0.5µl 100µM (100pmol/µl) 
50pmol EUG3b primer 0.5µl 100µM (100pmol/µl) 
50pmol EUG3c primer 0.5µl 100µM (100pmol/µl) 
Template (RT reaction) 20.57µl - 
Total 100µl - 
 
Sequencing Reaction 
Component Volume Stock Conc. 
DTCS Maste Mix 3µl Proprietary 
10pmol primer 1µl 10µM (10pmol/µl) 
RNase-free H2O (16-x)µl - 
Template (variable) x µl - 
Total 20µl - 
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Thermal Cycler Profiles 
 
Oberste A and B 
1 Cycle 40 Cycles 1 Cycle 
38°C 10 minutes 95°C 30 seconds 70°C 5 minutes 
50°C 40 minutes 42°C 45 seconds 4°C ∞ 
95°C 3 minutes 65°C 30 seconds   
 
 
Casas 1st and 2nd  
1 Cycle 40 Cycles 1 Cycle 
38°C 10 minutes 95°C 30 seconds 70°C 5 minutes 
50°C 40 minutes 46°C 1 minute 4°C ∞ 
95°C 3 minutes 65°C 30 seconds   
 
 
Caro RT 
1 Cycle 
42°C 30 minutes 
95°C  5 minutes 
4°C   ∞ 
 
Caro PCR  
40 Cycles 1 Cycle 
95°C 20 seconds 72°C 10 minutes 
45°C 1 minute 4°C ∞ 
72°C 1 minute   
 
 
Sequencing 
35 Cycles 
96°C 20 seconds 
42°C  20 seconds 
60°C 3 minutes 
4°C   ∞ 
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Appendix II 
 
Two by Two Tables 
 
Oberste A   Screening Standard 
   positive negative 
222/292 positive 46 0 
1-Step negative 8 2 
      
   sensitivity 0.8518519 
   specificity 1 
   PPV 1 
    NPV 0.2 
 
Oberste B   Screening Standard 
   positive negative 
011/012/040 positive 36 0 
1-Step negative 18 2 
      
   sensitivity 0.6666667 
   specificity 1 
   PPV 1 
    NPV 0.1 
 
Casas 1st   Screening Standard 
   positive negative 
1A/1S positive 30 0 
1-Step negative 24 2 
      
   sensitivity 0.5555556 
   specificity 1 
   PPV 1 
    NPV 0.0769231 
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Casas 2nd   Screening Standard 
   positive negative 
2A/2S (unnested) positive 16 0 
1-Step negative 38 2 
      
   sensitivity 0.2962963 
   specificity 1 
   PPV 1 
    NPV 0.05 
 
Casas Nested   Screening Standard 
   positive negative 
1A/1S-2A/2S positive 20 0 
1-Step x 2 negative 34 2 
Nested     
   sensitivity 0.3703704 
   specificity 1 
   PPV 1 
    NPV 0.0555556 
 
Caro   Screening Standard 
   positive negative 
EUC/EUG positive 40 0 
2-Step negative 14 2 
      
   sensitivity 0.7407407 
   specificity 1 
   PPV 1 
    NPV 0.125 
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Appendix III 
CB5 Alignment 
 
+ Majori
C C G G C A G A C A C T A T G C A G A C C A G A C A C G T G Majority
10 20 30
C C G G C A G A C A C T A T G C A G A C C A G A C A C G T G  29 c
C C G G C A G A C A C T A T G C A G A C C A G A C A C G T G  29 e
C C G G C A G A C A C T A T G C A G A C C A G A C A C G T G  29 d
C C G G C G G A C A C T A T G C A G A C C A G G C A C G T G  29 o
C C A G C A G A C A C T A T G C A G A C C A G A C A C G T G  29 g
C C G G C A G A T A C T A T G C A G A C C A G A C A C G T G  10 h
C C G G C A G A T A C T A T G C A G A C C A G A C A C G T G  8 i
C C A G C A G A C A C T A T G C A G A C C A G A C A C G T G  12 j
C C G G C A G A C A C T A T G C A G A C C A G A C A C G T G  35 k
C C G G C A G A C A C T A T G C A G A C C A G G C A C G T G  1 l
C C G G C A G A C A C T A T G C A G A C C A G G C A C G T G  29 m
C C G G C A G A C A C T A T G C A G A C C A G G C A C G T G  35 n
C C G G C A G A C A C T A T G C A G A C C A G A C A C G T G  38 f
+ Majori
A A A A A T T A T C A C T C G C G T T C T G A G T C C A C G Majority
40 50 60
A A G A A T T A T C A C T C G C G T T C T G A G T C C A C G  59 c
A A A A A T T A T C A C T C G C G T T C T G A G T C C A C G  59 e
A A G A A T T A T C A C T C G C G T T C T G A G T C C A C G  59 d
A A A A A T T A T C A C T C G C G T T C T G A G T C C A C G  59 o
A A A A A T T A T C A C T C G C G T T C T G A G T C C A C G  59 g
A A G A A T T A T C A C T C G C G T T C T G A G T C C A C A  40 h
A A G A A T T A T C A C T C G C G T T C T G A G T C C A C A  38 i
A A A A A T T A T C A C T C G C G T T C T G A G T C C A C G  42 j
A A A A A T T A T C A C T C G C G T T C T G A G T C C A C G  65 k
A A A A A T T A T C A C T C G C G T T C T G A G T C C A C G  31 l
A A A A A T T A T C A C T C G C G T T C T G A G T C C A C G  59 m
A A A A A T T T T C A C T C G C G T T C T G A G T C C A C G  65 n
A A G A A C T A T C A C T C A C G T T C T G A G T C C A C G68 f
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CB5 Alignment 
 
 
 
 
+ Majori
G T A G A G A A T T T C C T G T G T A G A T C T G C G T G T Majority
70 80 90
G T G G A G A A T T T C C T G T G T A G A T C T G C G T G T  89 c
G T A G A A A A T T T C C T G T G T A G A T C T G C G T G T  89 e
G T A G A G A A T T T C C T G T G T A G A T C T G C G T G T  89 d
G T A G A G A A T T T C C T G T G T A G A T C T G C G T G T  89 o
G T A G A G A A T T T C C T G T G T A G A T C T G C G T G T  89 g
G T A G A G A A T T T C C T G T G T A G A T C T G C G T G T  70 h
G T A G A G A A T T T C C T G T G T A G A T C T G C G T G T  68 i
G T A G A G A A T T T C C T G T G T A G A T C T G C G T G T  72 j
G T A G A G A A T T T C C T G T G T A G A T C T G C G T G T  95 k
G T A G A G A A T T T C C T G T G T A G A T C T G C G T G T  61 l
G T A G A G A A T T T C C T G T G C A G A T C T G C G T G T  89 m
G T A G A G A A T T T C C T G T G T A G A T C T G C G T G T  95 n
G T A G A G A A T T T C T T G T G T A G A T C T G C G T G T  98 f
+ Majori
G T A T A C T A T A C T A C C T A T A A G A A T C A T G G C Majority
100 110 120
G T A T A C T A T A C T A C C T A T A A G A A T C A T G G C  119 c
G T A T A C T A T A C T A C C T A T A A G A A T C A T G G C  119 e
G T A T A C T A T A C T A C C T A T A A G A A T C A T G G C  119 d
G T A T A C T A T A C A A C C T A T A A G A A T C A T G G C  119 o
G T A T A C T A T A C T A C C T A T A A A A A T C A T G G C  119 g
G T G T A T T A T A C T A C T T A C A A G A A T C A T G G C  100 h
G T G T A T T A T A C T A C T T A C A A G A A T C A T G G C  98 i
G T A T A C T A T A C C A C T T A T A A A A A T C A T G G C  102 j
G T A T A C T A T A C T A C C T A T A A A A A T C A T G G C  125 k
G T A T A C T A T A C T A C C T A T A A G A A T C A T G G C  91 l
G T A T A C T A T A C T A C C T A T A A G A A T C A T G G C  119 m
G T A T A C T A T A C C A C C T A T A A G A A T C A T G G C  125 n
G T A T A T T A C A C T A C T T A T A A G A A C C A T G G C  128 f
+ Majori
A C C G A T G G T G A C A A T T T T G C C T A T T G G G T G Majority
130 140 150
A C C G A T G G T G A C A A T T T T G C C T A T T G G G T G  149 c
A C C G A T G G T G A C A A T T T T G C C T A T T G G G T G  149 e
A C C G A T G G T G A C A A T T T T G C C T A T T G G G T G  149 d
A C C G A T G G T G A C A A T T T T G C C T A T T G G G T G  149 o
A C C G A T G G C G A C A A T T T T G C C T A T T G G G T G  149 g
A C C G A T G G C G A C A A T T T T G C C T A T T G G G T G  130 h
A C C G A T G G T G A T A A T T T T G C C T A T T G G G T G  128 i
A C C G A T G G C G A T A A T T T T G C C T A T T G G G T G  132 j
A C C G A T G G T G A C A A T T T T G C C T A T T G G G T G  155 k
A C C G A T G G T G A C A A T T T T G C C T A T T G G G T G  121 l
A C C G A T G G T G A C A A T T T T G C C T A T T G G G T G  149 m
A C C G A T G G T G A C A A T T T T G C C T A T T G G G T G  155 n
A C C G A C G G T G A C A A T T T T G C C T A T T G G G T G158 f
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CB5 Alignment (cont’d) 
 
 
 
 
+ Majori
A T T A A T A C A A G A C A G G T T G C G C A A T T A C G C Majority
160 170 180
A T T A A T A C A A G A C A G G T T G C G C A A T T A C G C  179 c
A T T A A T A C A A G A C A G G T T G C G C A A T T A C G C  179 e
A T T A A T A C A A G A C A G G T T G C G C A A T T A C G C  179 d
A T C A A T A C A A G A C A G G T T G C G C A A T T A C G C  179 o
A T T A A T A C A A G A C A G G T T G C G C A A T T G C G C  179 g
A T T A A T A C A A G A C A G G T T G C G C A A C T A C G C  160 h
A T T A A T A C A C G A C A G G T T G C G C A A C T A C G C  158 i
A T T A A T A C A A G A C A G G T T G C G C A A T T G C G C  162 j
A T T A A T A C A A G A C A G G T T G C G C A A T T A C G C  185 k
A T T A A T A C A A G A C A G G T T G C G C A A T T G C G C  151 l
A T T A A T A C A A G A C A G G T T G C G C A A T T A C G C  179 m
A T T A A T A C A A G A C A G G T T G C G C A A T T A C G C  185 n
A T T A A C A C A A G A C A G G T T G C G C A A C T A C G A  188 f
+ Majori
C G C A A A T T G G A A A T G T T C A C A T A T G C C A G A Majority
190 200 210
C G C A A A T T G G A A A T G T T C A C A T A T G C C A G A  209 c
C G C A A A T T G G A A A T G T T C A C A T A T G C C A G A  209 e
C G C A A A T T G G A A A T G T T T A C A T A T G C C A G A  209 d
C G C A A A T T G G A A A T G T T C A C A T A T G C C A G A  209 o
C G C A A A T T G G A A A T G T T C A C A T A T G C C A G A  209 g
C G C A A A T T G G A A A T G T T C A C A T A T G C C A G A  190 h
C G C A A A T T G G A A A T G T T C A C A T A T G C C A G A  188 i
C G C A A A T T G G A A A T G T T C A C A T A T G C C A G A  192 j
C G C A A A T T G G A G A T G T T C A C A T A T G C C A G A  215 k
C G C A A A T T G G A A A T G T T C A C A T A T G C C A G A  181 l
C G C A A A T T G G A A A T G T T C A C A T A T G C C A G A  209 m
C G C A A A T T G G A A A T G T T C A C A T A T G C C A G A  215 n
C G T A A A T T G G A A A T G T T C A C A T A T G C C A G A  218 f
+ Majori
T T T G A T T T G G A G C T T A C C T T T G T G A T A A C A Majority
220 230 240
T T T G A T T T G G A G C T C A C C T T T G T T A T A A C A  239 c
T T T G A T T T G G A G C T T A C C T T T G T G A T A A C A  239 e
T T T G A T T T G G A G C T C A C C T T T G T G A T A A C A  239 d
T T T G A T T T G G A G C T T A C T T T T G T G A T A A C A  239 o
T T T G A C T T G G A G C T T A C C T T T G T G A T A A C A  239 g
T T T G A T T T G G A A C T C A C C T T T G T G A T A A C A  220 h
T T T G A T T T G G A G C T C A C C T T T G T G A T A A C A  218 i
T T T G A C T T G G A G C T T A C C T T T G T A A T A A C A  222 j
T T T G A T T T G G A G C T T A C C T T T G T G A T A A C A  245 k
T T T G A T T T G G A G C T T A C T T T T G T G A T A A C A  211 l
T T T G A T T T G G A G C T T A C T T T T G T G A T A A C A  239 m
T T T G A T T T G G A G C T T A C T T T T G T G A T A A C A  245 n
T T T G A T T T G G A G C T C A C C T T T G T G G T A A C A248 f
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CB5 Alignment (cont’d) 
 
 
 
+ Majori
A G C A C A C A A G A G C A A T Majority
250
A G C A C A C A A G A G C A A T                269 c
A G C A C A C A A G A G C A A T                269 e
A G C A C A C A A G A G C A A T                269 d
A G C A C A C A A G A G C A A T                269 o
A G C A C A C A A G A G C A A T                269 g
A G C A C A C A A G A G C A A T                250 h
A G C A C A C A A G A G C A A T                248 i
A G C A C A C A A G A G C A A T                252 j
A G C A C A C A A G A G C A A T                275 k
A G C A C A C A A G A G C A A T                241 l
A G C A C A C A A G A G C A A T                269 m
A G C A C A C A A G A G C A A T                275 n
A G C A C A C A A G A G C A A T278 f
  78 
 
 
 
 
Appendix IV 
Possible Algorithm for Molecular-Based Enterovirus Serotyping 
Real-Time Screening Assay in conjunction with Arbovirus Taqman RT-PCR
BGM/RMK Cell Culture
Harvest at 3/3+ CPE
RNeasy Extraction, One-Step RT-PCR
Band excision, QIAquik Clean-up, quantification gel
Sequencing
Contig assembly, BLAST search 
 
